NZ333357A - Reduction of cardiotoxicity of an antitumor agent using manganese compound - Google Patents

Reduction of cardiotoxicity of an antitumor agent using manganese compound

Info

Publication number
NZ333357A
NZ333357A NZ333357A NZ33335797A NZ333357A NZ 333357 A NZ333357 A NZ 333357A NZ 333357 A NZ333357 A NZ 333357A NZ 33335797 A NZ33335797 A NZ 33335797A NZ 333357 A NZ333357 A NZ 333357A
Authority
NZ
New Zealand
Prior art keywords
cardiotoxicity
reduction
antitumor agent
manganese compound
chelate
Prior art date
Application number
NZ333357A
Other languages
English (en)
Inventor
Robertson Towart
Jan Olof Gustav Karlsson
Per Jynge
Original Assignee
Nycomed Imaging As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging As filed Critical Nycomed Imaging As
Publication of NZ333357A publication Critical patent/NZ333357A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/04Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture And Refinement Of Metals (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
NZ333357A 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound NZ333357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613182.6A GB9613182D0 (en) 1996-06-24 1996-06-24 Method
PCT/GB1997/001721 WO1997049390A1 (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound

Publications (1)

Publication Number Publication Date
NZ333357A true NZ333357A (en) 2000-08-25

Family

ID=10795775

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ333357A NZ333357A (en) 1996-06-24 1997-06-24 Reduction of cardiotoxicity of an antitumor agent using manganese compound
NZ333315A NZ333315A (en) 1996-06-24 1997-06-24 Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ333315A NZ333315A (en) 1996-06-24 1997-06-24 Dipyridoxyl chelating agents and their metal chelates for treating free radicals induced conditions

Country Status (14)

Country Link
US (2) US6258828B1 (cg-RX-API-DMAC10.html)
EP (2) EP0910360B1 (cg-RX-API-DMAC10.html)
JP (2) JP4359651B2 (cg-RX-API-DMAC10.html)
CN (2) CN1228694A (cg-RX-API-DMAC10.html)
AT (2) ATE225178T1 (cg-RX-API-DMAC10.html)
AU (2) AU720570B2 (cg-RX-API-DMAC10.html)
BR (1) BR9709942A (cg-RX-API-DMAC10.html)
CA (2) CA2258299A1 (cg-RX-API-DMAC10.html)
DE (2) DE69716104T2 (cg-RX-API-DMAC10.html)
GB (1) GB9613182D0 (cg-RX-API-DMAC10.html)
IL (1) IL127733A0 (cg-RX-API-DMAC10.html)
NO (2) NO985917L (cg-RX-API-DMAC10.html)
NZ (2) NZ333357A (cg-RX-API-DMAC10.html)
WO (2) WO1997049409A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727224D0 (en) * 1997-12-23 1998-02-25 Nycomed Imaging As Method
JP2001527072A (ja) * 1997-12-23 2001-12-25 ニユコメド・イメージング・アクシエセルカペト 一酸化窒素を放出するキレート化剤およびその治療上の使用
CN102038932B (zh) 1999-10-01 2013-11-06 Dmi生物科学公司 金属-结合性化合物及其用途
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
FR2823977B1 (fr) * 2001-04-26 2006-12-01 Univ Rene Descartes Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20040038904A1 (en) * 2002-05-21 2004-02-26 Angela Ogden Method of treating multiple sclerosis
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
ES2388064T3 (es) 2004-04-22 2012-10-08 Celator Pharmaceuticals, Inc. Formulaciones liposomales de agentes de antraciclina y análogos de citidina
ES2784794T3 (es) 2005-08-31 2020-10-01 Abraxis Bioscience Llc Composiciones que comprenden agentes farmacéuticos poco solubles en agua y agentes antimicrobianos
WO2009078794A1 (en) 2007-12-14 2009-06-25 Pledpharma Ab Compounds for use in the treatment of cancer
WO2011004325A1 (en) * 2009-07-06 2011-01-13 Pledpharma Ab Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound
DK2707030T3 (da) 2011-05-09 2020-05-18 Mayo Found Medical Education & Res Cancerbehandlinger
CN104169291B (zh) 2012-01-05 2017-08-15 普莱制药公司 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
AU2013327638B2 (en) 2012-10-01 2018-06-14 Mayo Foundation For Medical Education And Research Cancer treatments
BR112015009963A2 (pt) 2012-11-02 2017-07-11 Pledpharma Ab uso de compostos para a preparação de composições farmacêuticas para o tratamento de câncer
CN106573051B (zh) 2014-06-13 2021-07-13 梅约医药教育及研究基金会 治疗淋巴瘤
CN106604750B (zh) 2014-06-16 2021-05-07 梅约医学教育与研究基金会 治疗骨髓瘤
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
EP3432928A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP4177271A1 (en) 2016-09-01 2023-05-10 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
KR102486057B1 (ko) 2016-09-06 2023-01-10 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Pd-l1 발현 암의 치료 방법
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES444380A1 (es) * 1976-01-16 1977-06-16 Gosalvez Mario Un procedimiento para preparar derivados metalicos antraci- clinicos.
US4935518A (en) * 1987-05-08 1990-06-19 Salutar, Inc. Manganese(II), chelate contrast agents derived from N,N'-bis-(pyridoxal ethylene diamine-N,N')-diacetic acid and derivatives thereof
US4842845A (en) * 1987-05-08 1989-06-27 Salutar, Inc. Radioactive metal chelates for dipyridoxyl phosphate
US5223243A (en) * 1987-05-08 1993-06-29 Salutar, Inc. Dipyridoxyl phosphate chelating compound intermediates useful as NMRI contrast agents
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

Also Published As

Publication number Publication date
GB9613182D0 (en) 1996-08-28
ATE225178T1 (de) 2002-10-15
JP2000514044A (ja) 2000-10-24
EP0910360B1 (en) 2002-11-27
DE69717447D1 (de) 2003-01-09
NZ333315A (en) 2000-07-28
AU720621B2 (en) 2000-06-08
WO1997049390A1 (en) 1997-12-31
NO985916D0 (no) 1998-12-17
EP0936915B1 (en) 2002-10-02
CA2259150A1 (en) 1997-12-31
CN1228694A (zh) 1999-09-15
JP4359651B2 (ja) 2009-11-04
JP4162263B2 (ja) 2008-10-08
IL127733A0 (en) 1999-10-28
NO985917D0 (no) 1998-12-17
WO1997049409A1 (en) 1997-12-31
NO985916L (no) 1999-01-25
US6147094A (en) 2000-11-14
DE69716104D1 (de) 2002-11-07
EP0936915A1 (en) 1999-08-25
AU3268897A (en) 1998-01-14
AU3268997A (en) 1998-01-14
BR9709942A (pt) 1999-08-10
ATE228361T1 (de) 2002-12-15
AU720570B2 (en) 2000-06-08
CN1228703A (zh) 1999-09-15
DE69716104T2 (de) 2003-05-28
NO985917L (no) 1999-01-25
EP0910360A1 (en) 1999-04-28
CA2258299A1 (en) 1997-12-31
JP2000513351A (ja) 2000-10-10
US6258828B1 (en) 2001-07-10
DE69717447T2 (de) 2003-09-11

Similar Documents

Publication Publication Date Title
NZ333357A (en) Reduction of cardiotoxicity of an antitumor agent using manganese compound
AU3784193A (en) Reduction of swelling in hemorrhoidal tissues
CA2234282A1 (en) Drug-resin complexes stabilized by chelating agents
AU4299496A (en) Novel multiple-substituent dtpa derivatives and metal complexes thereof, pharmaceutical compositions containing such complexes, their use in diagnosis and therapy, methods ofpreparing the complexing agents and complexes and methods of preparing the pharmaceutical compositions
CA2222676A1 (en) New pharmaceutical composition with anaesthetic effect
CA2086429A1 (fr) Composition pharmaceutique ou cosmetique contenant en association un retinoide et un sterol
ZA945546B (en) Antifugal nail solution
CA2001765A1 (en) Chelants possessing ortho ligating functionality and complexes thereof
AU6959694A (en) Antineoplastic compositions and methods of use
CA2202531A1 (en) Lyophilizate of lipid complex of water insoluble camptothecins
AU2630295A (en) 2-acylaminopropanol compound and medical composition
AU8739791A (en) Improved anti-plaque compositions comprising a combination of morpholinoamino alcohol and chelating agent
WO1996041627A3 (en) Iron compounds, compositions, methods of making the same and uses thereof
AU3892593A (en) Composition for therapeutic or diagnostic use, process for its preparation and its use
GB9509882D0 (en) CRT adhesive composition and CRT obtained by the use thereof
AU3674595A (en) Antianemic agent containing iron and difructose
AU2821295A (en) Compositions and methods for the treatment of tumors
AU2729192A (en) Carboxyalkyl polysaccharides having improved absorbent properties and process for the preparation thereof
CA2116829A1 (en) Use of a pregnane derivative
AU7997491A (en) Extended-release plaque preventing and dissolving compositions and their method of use
HUT75641A (en) New compounds with analgesic and local anaesthetic effect
AU2022595A (en) Anti-sun cosmetic composition based on a synergic mixture ofscreening agents and uses
IL116733A (en) Sertraline for use as an anticancer agent compositions containing same preparation and uses thereof
AU1214792A (en) Chelates, their metal complexes as well as their use in diagnosis and treatment
AU2554595A (en) Compositions and uses thereof in the diagnosis of psoriasis

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)